إظهار الرسائل ذات التسميات الصفحة الرئسية. إظهار كافة الرسائل
إظهار الرسائل ذات التسميات الصفحة الرئسية. إظهار كافة الرسائل
الأربعاء، 24 يوليو 2013
الخميس، 27 يونيو 2013
الخميس، 20 يونيو 2013
Urine Test Identifies Risk of Necrotizing Enterocolitis
Urine Test Identifies Risk of Necrotizing Enterocolitis
By Labmedica International staff writers Posted on 30 Apr 2013
In premature babies, abnormal gut bacteria can be found days before the
onset of the devastating intestinal disease known as necrotizing
enterocolitis (NEC).
Examination of stool samples from preterm infants by molecular
techniques and urinary metabolomic analysis has revealed differences
between those at risk of NEC and those who will not develop the disease.
Scientists at Cincinnati Children's Hospital (OH, USA) collaborating
with other institutes, studied between October 2009 and August 2010, a
total of 35 preterm infants of less than 29 weeks gestational age and
whose weight was less than 1,200 grams at birth, The primary analysis
included 11 infants who developed NEC and 21 control infants. The infant
microbiome was analyzed by postnatal periods, 4 to 9 days and 10 to 16
days.
Bacterial DNA was extracted from infant stool samples using one of two
methods: phenol-chloroform or the QiaAmp DNA stool kit (Qiagen Sciences;
Germantown, MD, USA). The 16S ribosomal ribonucleic acid ( rRNA) gene
was amplified and sequenced using 454 FLX Titanium sequencing (454 Life
Sciences, Branford, CT, USA). Urine samples were analyzed by nuclear
magnetic resonance.
الأربعاء، 19 يونيو 2013
Prostate Cancer Genetic Tests Predicts Prognosis
Prostate Cancer Genetic Tests Predicts Prognosis
By Labmedica International staff writers
Posted on 21 Jan 2013
Posted on 21 Jan 2013
Diagnostic and prognostic genetic tests have been developed to better
predict prostate cancer survival outcomes and distinguish clinically
relevant cancers.
The diagnostic test distinguished patients with clinically relevant prostate cancer from normal prostate in men with elevated prostate-specific antigen (PSA) levels, and prognostic tests separate out men who died of prostate cancer versus those who lived.
Scientists at the Kimmel Cancer Center (Philadelphia, PA, USA) performed a retrospective analysis of over 350 patients using an oncogene-specific prostate cancer molecular signature, based on studies carried out in mice. They worked with three oncogenes previously associated with poorer outcomes in prostate cancer: avian myelocytomatosis viral oncogene homolog (c-Myc), Harvey rat sarcoma viral oncogene homolog (Ha-Ras), and sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (v-Src).
The diagnostic test distinguished patients with clinically relevant prostate cancer from normal prostate in men with elevated prostate-specific antigen (PSA) levels, and prognostic tests separate out men who died of prostate cancer versus those who lived.
Scientists at the Kimmel Cancer Center (Philadelphia, PA, USA) performed a retrospective analysis of over 350 patients using an oncogene-specific prostate cancer molecular signature, based on studies carried out in mice. They worked with three oncogenes previously associated with poorer outcomes in prostate cancer: avian myelocytomatosis viral oncogene homolog (c-Myc), Harvey rat sarcoma viral oncogene homolog (Ha-Ras), and sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (v-Src).
الأربعاء، 29 مايو 2013
الاثنين، 27 مايو 2013
الثلاثاء، 21 مايو 2013
السبت، 18 مايو 2013
الاشتراك في:
الرسائل (Atom)